Skip to main content

Advertisement

Articles

Page 7 of 35

  1. Dysglycaemia defined as type 2 diabetes (T2DM) and impaired glucose tolerance (IGT), increases the risk of cardiovascular disease (CVD). The negative impact is more apparent in the presence of hypertension and...

    Authors: Bahira Shahim, Viveca Gyberg, Dirk De Bacquer, Kornelia Kotseva, Guy De Backer, Oliver Schnell, Jaakko Tuomilehto, David Wood and Lars Rydén

    Citation: Cardiovascular Diabetology 2018 17:21

    Content type: Original investigation

    Published on:

  2. Metformin is the standard first-line drug for patients with Type 2 diabetes (T2DM). However, the optimal second-line oral anti-diabetic agent (ADA) remains unclear. We investigated the cardiovascular risk of v...

    Authors: Cheng-Wei Chan, Chu-Leng Yu, Jiunn-Cherng Lin, Yu-Cheng Hsieh, Che-Chen Lin, Chen-Ying Hung, Cheng-Hung Li, Ying-Chieh Liao, Chu-Pin Lo, Jin-Long Huang, Ching-Heng Lin and Tsu-Juey Wu

    Citation: Cardiovascular Diabetology 2018 17:20

    Content type: Original investigation

    Published on:

  3. Depression is a prevalent, independent predictor of mortality in patients with heart failure (HF). Depression is also common in type 2 diabetes mellitus (T2DM), which is itself an important risk factor for HF....

    Authors: Ying Wang, Hong Yang, Mark Nolan, John Burgess, Kazuaki Negishi and Thomas H. Marwick

    Citation: Cardiovascular Diabetology 2018 17:19

    Content type: Original investigation

    Published on:

  4. Patients with type-2 diabetes mellitus (T2DM) are at high risk of cardiovascular events, accentuated in the presence of hypertension. At present, it is unclear to what extent the guidelines for the management ...

    Authors: Roland E. Schmieder, Diethelm Tschöpe, Cornelia Koch, Taoufik Ouarrak and Anselm K. Gitt

    Citation: Cardiovascular Diabetology 2018 17:18

    Content type: Original investigation

    Published on:

  5. The severity of the metabolic syndrome (MetS) is significantly associated with future coronary heart disease (CHD) among individuals without baseline Type 2 diabetes. However, the validity of assessing MetS se...

    Authors: Matthew J. Gurka, Yi Guo, Stephanie L. Filipp and Mark D. DeBoer

    Citation: Cardiovascular Diabetology 2018 17:17

    Content type: Original investigation

    Published on:

  6. The risk of diabetic complications is modified by genetic and epigenetic factors. p66Shc drives the hyperglycaemic cell damage and its deletion prevents experimental diabetic complications. We herein tested wheth...

    Authors: Gian Paolo Fadini, Mattia Albiero, Benedetta Maria Bonora, Nicol Poncina, Saula Vigili de Kreutzenberg and Angelo Avogaro

    Citation: Cardiovascular Diabetology 2018 17:16

    Content type: Original investigation

    Published on:

  7. Increased reactive oxygen species (ROS) generation in diabetes mellitus (DM) is an important mechanism leading to diabetic cardiomyopathy. Apocynin, a drug isolated from the herb Picrorhiza kurroa, is considered ...

    Authors: R. Gimenes, C. Gimenes, C. M. Rosa, N. P. Xavier, D. H. S. Campos, A. A. H. Fernandes, M. D. M. Cezar, G. N. Guirado, L. U. Pagan, I. D. Chaer, D. C. Fernandes, F. R. Laurindo, A. C. Cicogna, M. P. Okoshi and K. Okoshi

    Citation: Cardiovascular Diabetology 2018 17:15

    Content type: Original investigation

    Published on:

  8. Haptoglobin (Hp) functions as an antioxidant by binding with haemoglobin. We investigated whether serum Hp has a causal effect on macroangiopathy via Mendelian randomization (MR) analysis with common variants ...

    Authors: Shiyun Wang, Jie Wang, Rong Zhang, Tao Wang, Dandan Yan, Zhen He, Feng Jiang, Cheng Hu and Weiping Jia

    Citation: Cardiovascular Diabetology 2018 17:14

    Content type: Original investigation

    Published on:

  9. Measurement of systolic and diastolic function in animal models is challenging by conventional non-invasive methods. Therefore, we aimed at comparing speckle-tracking echocardiography (STE)-derived parameters ...

    Authors: Csaba Mátyás, Attila Kovács, Balázs Tamás Németh, Attila Oláh, Szilveszter Braun, Márton Tokodi, Bálint András Barta, Kálmán Benke, Mihály Ruppert, Bálint Károly Lakatos, Béla Merkely and Tamás Radovits

    Citation: Cardiovascular Diabetology 2018 17:13

    Content type: Original investigation

    Published on:

  10. The distribution of glucose and fatty-acid transporters in the heart is crucial for energy consecution and myocardial function. In this sense, the glucagon-like peptide-1 (GLP-1) enhancer, sitagliptin, improve...

    Authors: E. Ramírez, B. Picatoste, A. González-Bris, M. Oteo, F. Cruz, A. Caro-Vadillo, J. Egido, J. Tuñón, M. A. Morcillo and Ó. Lorenzo

    Citation: Cardiovascular Diabetology 2018 17:12

    Content type: Original investigation

    Published on:

  11. Albuminuria is of one the strongest predictors of cardiovascular disease (CVD) in diabetes. Diabetes is associated with cardiac microvascular dysfunction (CMD), a powerful, independent prognostic factor for ca...

    Authors: Louis Potier, Renata Chequer, Ronan Roussel, Kamel Mohammedi, Souad Sismail, Agnès Hartemann, Chloé Amouyal, Michel Marre, Dominique Le Guludec and Fabien Hyafil

    Citation: Cardiovascular Diabetology 2018 17:11

    Content type: Original investigation

    Published on:

  12. Statins are widely used for lipid lowering in patients with coronary artery disease (CAD), but increasing evidence indicates an association between statin use and new-onset of diabetes mellitus (NODM). Epicard...

    Authors: Jeehoon Kang, Young-Chan Kim, Jin Joo Park, Sehun Kim, Si-Hyuck Kang, Young Jin Cho, Yeonyee E. Yoon, Il-Young Oh, Chang-Hwan Yoon, Jung-Won Suh, Young-Seok Cho, Tae-Jin Youn, In-Ho Chae and Dong-Ju Choi

    Citation: Cardiovascular Diabetology 2018 17:10

    Content type: Original investigation

    Published on:

  13. Drugs that inhibit dipeptidyl peptidase-4 (DPP-4) are conventionally regarded as incretin-based agents that signal through the glucagon-like peptide-1 (GLP-1) receptor. However, inhibition of DPP-4 also potent...

    Authors: Milton Packer

    Citation: Cardiovascular Diabetology 2018 17:9

    Content type: Review

    Published on:

  14. Incretin-based therapies are used in the treatment of type 2 diabetes mellitus (T2DM) and obesity. We investigated the changes in arterial stiffness and left ventricular (LV) myocardial deformation after 6-mon...

    Authors: Vaia Lambadiari, George Pavlidis, Foteini Kousathana, Maria Varoudi, Dimitrios Vlastos, Eirini Maratou, Dimitrios Georgiou, Ioanna Andreadou, John Parissis, Helen Triantafyllidi, John Lekakis, Efstathios Iliodromitis, George Dimitriadis and Ignatios Ikonomidis

    Citation: Cardiovascular Diabetology 2018 17:8

    Content type: Original investigation

    Published on:

  15. Cardiac magnetic resonance (CMR) T1 mapping and tissue-tracking strain analysis are useful quantitative techniques that can characterize myocardial tissue and mechanical alterations, respectively, in patients ...

    Authors: Yukun Cao, Wenjuan Zeng, Yue Cui, Xiangchuang Kong, Miao Wang, Jie Yu, Shan Zhang, Jing Song, Xu Yan, Andreas Greiser and Heshui Shi

    Citation: Cardiovascular Diabetology 2018 17:7

    Content type: Original investigation

    Published on:

  16. Glycosuria produced by sodium–glucose co-transporter-2 (SGLT-2) inhibitors is associated with weight loss. SGLT-2 inhibitors reportedly might reduce the occurrence of cardiovascular events. Epicardial adipose ...

    Authors: Takao Sato, Yoshifusa Aizawa, Sho Yuasa, Shohei Kishi, Koichi Fuse, Satoshi Fujita, Yoshio Ikeda, Hitoshi Kitazawa, Minoru Takahashi, Masahito Sato and Masaaki Okabe

    Citation: Cardiovascular Diabetology 2018 17:6

    Content type: Original investigation

    Published on:

  17. Sodium tissue content by 23Na magnetic resonance imaging (Na-MRI) has been validated in experimental and human studies. SGLT-2 inhibition blocks the reabsorption of glucose and of sodium in the proximal tubular c...

    Authors: M. V. Karg, A. Bosch, D. Kannenkeril, K. Striepe, C. Ott, M. P. Schneider, F. Boemke-Zelch, P. Linz, A. M. Nagel, J. Titze, M. Uder and R. E. Schmieder

    Citation: Cardiovascular Diabetology 2018 17:5

    Content type: Original investigation

    Published on:

  18. Data on the influence of glycemic status on the progression of coronary calcification, an important marker for future adverse cardiovascular events, are limited.

    Authors: Ki-Bum Won, Donghee Han, Ji Hyun Lee, Sang-Eun Lee, Ji Min Sung, Su-Yeon Choi, Eun Ju Chun, Sung Hak Park, Hae-Won Han, Jidong Sung, Hae Ok Jung and Hyuk-Jae Chang

    Citation: Cardiovascular Diabetology 2018 17:4

    Content type: Original investigation

    Published on:

  19. A recent study found that among individuals with a preserved left ventricular ejection fraction ≥ 55%, global longitudinal strain was significantly lower in overweight patients (i.e., body mass index ≥ 25 kg/m2) ...

    Authors: Katrine Dina Musaeus and Manan Pareek

    Citation: Cardiovascular Diabetology 2018 17:3

    Content type: Commentary

    Published on:

  20. The cardiovascular safety and efficacy of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) after acute coronary syndrome (ACS) or acute ischemic stroke (AIS) ar...

    Authors: Yan-Rong Li, Sung-Sheng Tsai, Dong-Yi Chen, Szu-Tah Chen, Jui-Hung Sun, Hung-Yu Chang, Miaw-Jene Liou and Tien-Hsing Chen

    Citation: Cardiovascular Diabetology 2018 17:2

    Content type: Original investigation

    Published on:

  21. NG-Methylation of l-arginine (Arg) residues in certain proteins by protein arginine methyltransferases and subsequent proteolysis yields NG-monomethyl-l-arginine (MMA), NG,NG-dimethyl-l-arginine (asymmetric dimet...

    Authors: Dimitrios Tsikas, Alexander Bollenbach, Erik Hanff and Arslan Arinc Kayacelebi

    Citation: Cardiovascular Diabetology 2018 17:1

    Content type: Commentary

    Published on:

  22. Attenuated increases in ventricular stroke volume during exercise are common in type 2 diabetes and contribute to reduced aerobic capacity. The purpose of this study was to determine whether impaired ventricul...

    Authors: Genevieve A. Wilson, Gerard T. Wilkins, Jim D. Cotter, Regis R. Lamberts, Sudish Lal and James C. Baldi

    Citation: Cardiovascular Diabetology 2017 16:160

    Content type: Original investigation

    Published on:

  23. Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF ass...

    Authors: Chia-Yu Chang, Yung-Hsin Yeh, Yi-Hsin Chan, Jia-Rou Liu, Shang-Hung Chang, Hsin-Fu Lee, Lung-Sheng Wu, Kun-Chi Yen, Chi-Tai Kuo and Lai-Chu See

    Citation: Cardiovascular Diabetology 2017 16:159

    Content type: Original investigation

    Published on:

  24. Elevated levels of low-density lipoprotein cholesterol (LDL-C) and glycosylated hemoglobin (HbA1c) are risk factors for cardiovascular complications. This study evaluated LDL-C goal attainment in Russian clini...

    Authors: Sergey Boytsov, Natalia Logunova and Yunona Khomitskaya

    Citation: Cardiovascular Diabetology 2017 16:158

    Content type: Original investigation

    Published on:

  25. Hyperglycemia is associated with increased morbidity and mortality in patients with an acute myocardial infarction (AMI). We evaluated whether complications after AMI are associated with absolute or relative g...

    Authors: Tien F. Lee, Morton G. Burt, Leonie K. Heilbronn, Arduino A. Mangoni, Vincent W. Wong, Mark McLean and N. Wah Cheung

    Citation: Cardiovascular Diabetology 2017 16:157

    Content type: Original investigation

    Published on:

  26. Coronary atherosclerosis progresses faster in patients with diabetes mellitus (DM) and causes higher morbidity and mortality in such patients compared to non-diabetics ones (non-DM). We quantify changes in pla...

    Authors: Tomas Kovarnik, Zhi Chen, Gary S. Mintz, Andreas Wahle, Kristyna Bayerova, Ales Kral, Martin Chval, Karel Kopriva, John Lopez, Milan Sonka and Ales Linhart

    Citation: Cardiovascular Diabetology 2017 16:156

    Content type: Original investigation

    Published on:

  27. Cardiovascular disease, predominantly ischemic heart disease (IHD), is the leading cause of death in diabetes mellitus (DM). In addition to eliciting cardiomyopathy, DM induces a ‘wicked triumvirate’: (i) incr...

    Authors: Jake Russell, Eugene F. Du Toit, Jason N. Peart, Hemal H. Patel and John P. Headrick

    Citation: Cardiovascular Diabetology 2017 16:155

    Content type: Review

    Published on:

  28. The potential of anti-aging effect of DPP-4 inhibitors is unknown. This study was performed to determine whether linagliptin, a DPP-4 inhibitor, could protect against premature aging in klotho−/− mice.

    Authors: Yu Hasegawa, Kenyu Hayashi, Yushin Takemoto, Cao Cheng, Koki Takane, Bowen Lin, Yoshihiro Komohara and Shokei Kim-Mitsuyama

    Citation: Cardiovascular Diabetology 2017 16:154

    Content type: Original investigation

    Published on:

  29. Biomarkers of inflammation and adiponectin are associated with cardiovascular autonomic neuropathy (CAN) in cross-sectional studies, but prospective data are scarce. This study aimed to assess the associations...

    Authors: Christian Stevns Hansen, Dorte Vistisen, Marit Eika Jørgensen, Daniel R. Witte, Eric J. Brunner, Adam G. Tabák, Mika Kivimäki, Michael Roden, Marek Malik and Christian Herder

    Citation: Cardiovascular Diabetology 2017 16:153

    Content type: Original investigation

    Published on:

  30. Patients with type 2 diabetes (T2DM) are at high risk for cardiovascular events, which usually arise from the rupture of a vulnerable coronary plaque. The minimal fibrous cap thickness (FCT) overlying a necrot...

    Authors: Andrea Milzi, Mathias Burgmaier, Kathrin Burgmaier, Martin Hellmich, Nikolaus Marx and Sebastian Reith

    Citation: Cardiovascular Diabetology 2017 16:152

    Content type: Original investigation

    Published on:

  31. Diabetes mellitus is considered an important risk factor for cardiovascular diseases. High hemoglobin A1c (HbA1c) levels, which indicate poor glycemic control, have been associated with occurrence of cardiovas...

    Authors: Shohei Ouchi, Kazunori Shimada, Tetsuro Miyazaki, Shuhei Takahashi, Yurina Sugita, Megumi Shimizu, Azusa Murata, Tomoyasu Kadoguchi, Takao Kato, Tatsuro Aikawa, Shoko Suda, Eiryu Sai, Masaru Hiki, Hiroshi Iwata, Takatoshi Kasai, Katsumi Miyauchi…

    Citation: Cardiovascular Diabetology 2017 16:151

    Content type: Original investigation

    Published on:

  32. Following publication of the original article [1], the authors identified a number of errors. In Result (P.3), Table 1 (P.4), Table 5 (P.9) and Supplementary Table 1, the correct unit for adiponectin was μg/mL. I...

    Authors: Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi, Saki Yamamoto, Masako Tomoyasu, Anna Osamura, Makoto Ohara, Takeshi Yamamoto, Yasuki Ito and Tsutomu Hirano

    Citation: Cardiovascular Diabetology 2017 16:149

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2017 16:8

  33. Hypoglycemia is associated with increased mortality rate in patients with diabetes. The underlying mechanisms may involve reduced myocardial tolerance to ischemia and reperfusion (IR) or reduced capacity for i...

    Authors: Kim B. Pælestik, Nichlas R. Jespersen, Rebekka V. Jensen, Jacob Johnsen, Hans Erik Bøtker and Steen B. Kristiansen

    Citation: Cardiovascular Diabetology 2017 16:148

    Content type: Original investigation

    Published on:

  34. Irisin is a hormone released mainly from skeletal muscle after exercise which increases adipose tissue energy expenditure. Adipocytes can also release irisin after exercise, acting as a local adipokine to indu...

    Authors: Karan S. Rana, Chathyan Pararasa, Islam Afzal, David A. Nagel, Eric J. Hill, Clifford J. Bailey, Helen R. Griffiths, Ioannis Kyrou, Harpal S. Randeva, Srikanth Bellary and James E. Brown

    Citation: Cardiovascular Diabetology 2017 16:147

    Content type: Original investigation

    Published on:

  35. The cardiovascular benefits of statins have been proven, but their effect on circulation in small vessels has not been examined fully. We investigated the effect of 20 mg rosuvastatin on biomarkers, including ...

    Authors: Kyoung Min Kim, Kyong Yeun Jung, Han Mi Yun, Seo Young Lee, Tae Jung Oh, Hak Chul Jang and Soo Lim

    Citation: Cardiovascular Diabetology 2017 16:146

    Content type: Original investigation

    Published on:

    The Retraction Note to this article has been published in Cardiovascular Diabetology 2019 18:32

  36. Coexistence of left ventricular (LV) longitudinal myocardial systolic dysfunction with LV diastolic dysfunction could lead to heart failure with preserved ejection fraction (HFpEF). Diabetes mellitus (DM) is k...

    Authors: Makiko Suto, Hidekazu Tanaka, Yasuhide Mochizuki, Jun Mukai, Hiroki Takada, Fumitaka Soga, Kumiko Dokuni, Yutaka Hatani, Keiko Hatazawa, Hiroki Matsuzoe, Hiroyuki Sano, Hiroyuki Shimoura, Junichi Ooka, Kensuke Matsumoto, Yushi Hirota, Wataru Ogawa…

    Citation: Cardiovascular Diabetology 2017 16:145

    Content type: Original investigation

    Published on:

  37. Type 2 diabetes mellitus (T2DM) is strongly related to the in-hospital and short-term prognosis in patients with cardiovascular diseases needing surgical or invasive interventions. How T2DM might influence the...

    Authors: Manuel Mendez-Bailon, Noel Lorenzo-Villalba, Nuria Muñoz-Rivas, Jose Maria de Miguel-Yanes, Javier De Miguel-Diez, Josep Comín-Colet, Valentin Hernandez-Barrera, Rodrigo Jimenez-Garcia and Ana Lopez-de-Andres

    Citation: Cardiovascular Diabetology 2017 16:144

    Content type: Original investigation

    Published on:

  38. Macrophages play a pivotal role in atherosclerotic plaque development. Recent evidence has suggested the glucagon-like peptide-1 receptor (GLP-1R) agonist, liraglutide, can attenuate pro-inflammatory responses...

    Authors: Robyn Bruen, Sean Curley, Sarina Kajani, Daniel Crean, Marcella E. O’Reilly, Margaret B. Lucitt, Catherine G. Godson, Fiona C. McGillicuddy and Orina Belton

    Citation: Cardiovascular Diabetology 2017 16:143

    Content type: Original investigation

    Published on:

  39. Diabetes mellitus is a risk factor for coronary artery disease and diabetic cardiomyopathy, and adversely impacts outcomes following coronary artery bypass grafting. Current treatments focus on macro-revascula...

    Authors: Masashi Kawamura, Michael J. Paulsen, Andrew B. Goldstone, Yasuhiro Shudo, Hanjay Wang, Amanda N. Steele, Lyndsay M. Stapleton, Bryan B. Edwards, Anahita Eskandari, Vi N. Truong, Kevin J. Jaatinen, Arnar B. Ingason, Shigeru Miyagawa, Yoshiki Sawa and Y. Joseph Woo

    Citation: Cardiovascular Diabetology 2017 16:142

    Content type: Original investigation

    Published on:

  40. We have previously shown that many chronic, inflammatory diseases are accompanied, and possibly partly caused or exacerbated, by various coagulopathies, manifested as anomalous clots in the form of ‘dense matt...

    Authors: Etheresia Pretorius, Martin J. Page, Lize Engelbrecht, Graham C. Ellis and Douglas B. Kell

    Citation: Cardiovascular Diabetology 2017 16:141

    Content type: Original investigation

    Published on:

  41. Pioglitazone (PIO), a thiazolidinediones drug, is a well-known anti-diabetic medicine, but its anti-atherosclerotic effects remain controversial. Thus it is important to investigate the effects of PIO on ather...

    Authors: Yuling Tian, Tao Chen, Yan Wu, Lin Yang, Lijun Wang, Xiaojuan Fan, Wei Zhang, Jiahao Feng, Hang Yu, Yanjie Yang, Juan Zhou, Zuyi Yuan and Yue Wu

    Citation: Cardiovascular Diabetology 2017 16:140

    Content type: Original investigation

    Published on:

  42. Altered regulation of extracellular matrix (ECM) composition by matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs) may contribute to arterial stiffening. We investigated associ...

    Authors: Stijn A. Peeters, Lian Engelen, Jacqueline Buijs, Nish Chaturvedi, John H. Fuller, Anders Jorsal, Hans-Henrik Parving, Lise Tarnow, Simone Theilade, Peter Rossing, Casper G. Schalkwijk and Coen D. A. Stehouwer

    Citation: Cardiovascular Diabetology 2017 16:139

    Content type: Original investigation

    Published on:

  43. Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardiovascular events in patients with type 2 diabetes through not fully elucidated mechanisms. Aim of this study was to inves...

    Authors: Anna Solini, Livia Giannini, Marta Seghieri, Edoardo Vitolo, Stefano Taddei, Lorenzo Ghiadoni and Rosa Maria Bruno

    Citation: Cardiovascular Diabetology 2017 16:138

    Content type: Original investigation

    Published on:

  44. These recommendations aim to improve care for patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk in Central and Eastern Europe. Cardiovascular disease (CVD) and/or chronic kidney disease (CKD...

    Authors: Guntram Schernthaner, Roger Lehmann, Martin Prázný, Leszek Czupryniak, Kristine Ducena, Peter Fasching, Andrej Janež, Avraham Karasik, Peter Kempler, Emil Martinka, Marina V. Shestakova, Lea Smirčić Duvnjak and Tsvetalina Tankova

    Citation: Cardiovascular Diabetology 2017 16:137

    Content type: Review

    Published on:

  45. This article was unintentionally published twice in this journal, by the same authors. The following should be considered the version of record and used for citation purposes: “Mehran Haidari, Wei Zhang, James...

    Authors: Mehran Haidari, Wei Zhang, James T. Willerson and Richard A. F. Dixon

    Citation: Cardiovascular Diabetology 2017 16:136

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2014 13:112

  46. Following publication of the original article [1], author Antonio Ceriello requested that a correction be published in relation to his affiliations. His correct affiliations have been updated in this erratum. Thi...

    Authors: Oliver Schnell, Eberhard Standl, Doina Catrinoiu, Stefano Genovese, Nebojsa Lalic, Jan Skra, Paul Valensi, Dario Rahelic and Antonio Ceriello

    Citation: Cardiovascular Diabetology 2017 16:135

    Content type: Correction

    Published on:

    The original article was published in Cardiovascular Diabetology 2017 16:35

  47. Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone trea...

    Authors: Marit de Jong, H. Bart van der Worp, Yolanda van der Graaf, Frank L. J. Visseren and Jan Westerink

    Citation: Cardiovascular Diabetology 2017 16:134

    Content type: Review

    Published on:

  48. Previous studies have demonstrated that secreted frizzled-related protein 4 (SFRP4) is associated with impaired glucose and triglyceride metabolism in patients with stable coronary artery disease. In the prese...

    Authors: Qingwei Ji, Jianwei Zhang, Yu Du, Enjun Zhu, Zhijian Wang, Bin Que, Huangtai Miao, Shutian Shi, Xiuchuan Qin, Yingxin Zhao, Yujie Zhou, Fangjun Huang and Shaoping Nie

    Citation: Cardiovascular Diabetology 2017 16:133

    Content type: Original investigation

    Published on:

Annual Journal Metrics

Advertisement